ASH 2019 | Gemtuzumab-based induction regimens produce higher rates of MRD negativity in CBF-AML
Jeffrey Lancet
• 8 Dec 2019
Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, discusses the study describing overall responses after standard inductions with high dose daunorubicin (90mg/m2) vs standard dose daunorubicin (60mg/m2) with gemtuzumab ozogamicin (GO) in favorable risk acute myeloid leukemia (AML). Incorporation of GO to 7+3 with standard dose daunorubicin resulted in comparable remission rates to 7+3 with high dose daunorubicin. Importantly, GO-based regimens produce higher rates of MRD negativity compared to 7+3 with high dose daunorubicin in CBF AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
